Live audio webcasts can be accessed through the Investor Relations page
of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA) have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen.
Custirsen is currently in Phase 3 clinical development as a treatment
in men with metastatic castrate-resistant prostate cancer. OGX-427 is
in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com